The overall Objective of Biospecimens Accessioning and Processing Shared Resource (BAP) is to provide a central facility to electronically accession and process biospecimens intended for research by Cancer Center members.
The Specific Aims of the Shared Resource are to: 1) provide electronic accessioning of biospecimens into a central Research Specimen Database, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, 4) to provide long term storage of processed Biospecimens in a secure and accessible facility, 5) to provide consultative services and specific expertise to Cancer Center investigators. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other body fluids. Blood specimens are processed for nucleic acid extraction, viable controlled rate freezing of mononuclear cells, and/or frozen storage of DNA, plasma, serum or buffy coats. DNA samples can be retrieved from a robotically controlled freezer, aliquoted into tubes or 96 well plates for downstream analyses, and returned to storage with little effort required from the investigator. Fresh solid tissues are dissected and frozen in liquid nitrogen or freezing medium. One of the most valuable contributions of the BAP resource is the specimen annotation that is entered into the Research Laboratory Information System (RLIMS) at the time of specimen accessioning and subsequently utilized for timely and appropriate retrieval of archived specimens. During the current funding period, BAP has expanded to include the Mayo Clinic Arizona (MCA) and Mayo Clinic Florida (MCF) BAP labs to become a three-site Shared Resource. In 2012, Rochester BAP Shared Resource processed over 100,000 blood tubes and extracted DNA from over 23,000 biospecimens for over 300 investigators at the Mayo Clinic, 34% of which are MCCC members. AZ-BAP processed almost 20,000 samples from over 400 IRB protocols representing 86 Mayo Clinic investigators, 2 1% of which are MCCC members. FL-BAP processed over 10,000 samples for over 25 Mayo Clinic investigators, of which 75% are MCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682945
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$208,899
Indirect Cost
$77,628
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications